CN110799537B - 抗pd-1抗体及其制备和使用方法 - Google Patents

抗pd-1抗体及其制备和使用方法 Download PDF

Info

Publication number
CN110799537B
CN110799537B CN201880038220.XA CN201880038220A CN110799537B CN 110799537 B CN110799537 B CN 110799537B CN 201880038220 A CN201880038220 A CN 201880038220A CN 110799537 B CN110799537 B CN 110799537B
Authority
CN
China
Prior art keywords
ser
thr
val
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880038220.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110799537A (zh
Inventor
布莱恩·科瓦切维奇
夏冬
安妮·詹森
乔纳森·K·法莱
布莱尔·伦肖
杰弗里·B·阿达莫
菲尔·谭
高泽人
朱义
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Bailidote Biological Pharmaceutical Co ltd
Original Assignee
Chengdu Bailidote Biological Pharmaceutical Co ltd
Seattle Immunization Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Bailidote Biological Pharmaceutical Co ltd, Seattle Immunization Co filed Critical Chengdu Bailidote Biological Pharmaceutical Co ltd
Publication of CN110799537A publication Critical patent/CN110799537A/zh
Application granted granted Critical
Publication of CN110799537B publication Critical patent/CN110799537B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880038220.XA 2017-06-25 2018-06-22 抗pd-1抗体及其制备和使用方法 Active CN110799537B (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762524554P 2017-06-25 2017-06-25
US201762524558P 2017-06-25 2017-06-25
US201762524557P 2017-06-25 2017-06-25
US201762524553P 2017-06-25 2017-06-25
US62/524,554 2017-06-25
US62/524,558 2017-06-25
US62/524,557 2017-06-25
US62/524,553 2017-06-25
US201762545603P 2017-08-15 2017-08-15
US62/545,603 2017-08-15
PCT/US2018/039147 WO2019005635A2 (en) 2017-06-25 2018-06-22 ANTI-PD-1 ANTIBODIES AND METHODS OF PREPARATION AND USE

Publications (2)

Publication Number Publication Date
CN110799537A CN110799537A (zh) 2020-02-14
CN110799537B true CN110799537B (zh) 2023-07-28

Family

ID=64742653

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880038220.XA Active CN110799537B (zh) 2017-06-25 2018-06-22 抗pd-1抗体及其制备和使用方法

Country Status (5)

Country Link
US (1) US11466084B2 (https=)
EP (1) EP3645740A4 (https=)
JP (2) JP7601635B2 (https=)
CN (1) CN110799537B (https=)
WO (1) WO2019005635A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
EP4011918A4 (en) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. DUAL SPECIFIC PROTEIN
CN116209466A (zh) * 2020-08-27 2023-06-02 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗鼻咽癌中的用途
EP4293046A4 (en) * 2021-02-10 2025-03-05 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anti-pd-1 antibody and use thereof
CN116687933B (zh) * 2022-02-28 2025-10-31 中国科学院上海药物研究所 甲氨蝶呤及其药物组合物在肿瘤免疫治疗中的用途
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
CN119775428B (zh) * 2024-12-12 2025-08-05 广东沃博生物医药科技有限公司 一种免疫细胞的制备方法及其在治疗疾病中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110621A1 (en) * 2010-03-11 2011-09-15 Ucb Pharma, S.A. Biological products: humanised agonistic anti-pd-1 antibodies
WO2015112800A1 (en) * 2014-01-23 2015-07-30 Regeneron Pharmaceuticals, Inc. Human antibodies to pd-1
CN105315373A (zh) * 2005-05-09 2016-02-10 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
HRP20131167T1 (hr) * 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
CA2920113A1 (en) * 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
SG10201900002QA (en) * 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
KR102524920B1 (ko) * 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
WO2017019846A1 (en) * 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
PL3368572T3 (pl) * 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315373A (zh) * 2005-05-09 2016-02-10 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2011110621A1 (en) * 2010-03-11 2011-09-15 Ucb Pharma, S.A. Biological products: humanised agonistic anti-pd-1 antibodies
WO2015112800A1 (en) * 2014-01-23 2015-07-30 Regeneron Pharmaceuticals, Inc. Human antibodies to pd-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Combination approaches with immune checkpoint blockade in cancer therapy;Maarten Swart等;《Frontiers in Oncology》;20161101;第6卷;XP055558918 *
小鼠抗人PD-1单克隆抗体的制备及其生物学活性评价;王冠英等;《免疫学杂志》;20170401(第04期);354-359 *

Also Published As

Publication number Publication date
JP7601635B2 (ja) 2024-12-17
JP7490109B2 (ja) 2024-05-24
US11466084B2 (en) 2022-10-11
CN110799537A (zh) 2020-02-14
EP3645740A2 (en) 2020-05-06
WO2019005635A2 (en) 2019-01-03
US20200157219A1 (en) 2020-05-21
JP2023107246A (ja) 2023-08-02
EP3645740A4 (en) 2021-08-18
JP2020529862A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
US20230340160A1 (en) Bispecific t cell activating antigen binding molecules
CN110799537B (zh) 抗pd-1抗体及其制备和使用方法
KR102025848B1 (ko) 항―ｎｇｆ 조성물 및 그의 용도
RU2753902C2 (ru) Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
CN108055848B (zh) 抗pacap抗体及其用途
DK2519543T3 (en) HETERODIMER BINDING PROTEINS AND USE THEREOF
CN107074955B (zh) 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
KR102361237B1 (ko) 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
AU2017250807A1 (en) Anti-PACAP antibodies and uses thereof
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
KR20180099723A (ko) 항-tl1a/항-tnf-알파 이중특이적 항원 결합 단백질 및 그의 용도
KR20150122761A (ko) Ｔ 세포 활성화 항원 결합 분자
AU2016280190B2 (en) Cys80 conjugated immunoglobulins
KR20200135935A (ko) 유도 및 네비게이션 제어 단백질 및 이의 제조 및 사용 방법
KR20150122203A (ko) T 세포 활성화 이중특이적 항원 결합 분자
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20220154710A (ko) 소형 유도 및 항법 제어(miniGNC) 항체-유사 단백질 및 이의 제조 및 사용 방법
TW202216743A (zh) Ｉｌ－１０突變蛋白及其融合蛋白
KR101981662B1 (ko) 형질전환된 미생물 예컨대 피치아 패스토리스에서 다중-서브유닛 단백질 예컨대 항체의 고순도 생산
AU2016273912B2 (en) High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
RU2838544C1 (ru) МИНИАТЮРНЫЕ АНТИТЕЛОПОДОБНЫЕ БЕЛКИ УПРАВЛЕНИЯ И НАВИГАЦИОННОГО КОНТРОЛЯ (miniGNC) И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
HK40020170A (en) Bispecific t cell activating antigen binding molecules
EA044746B1 (ru) АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ ПРОТИВ ГЛИКОПРОТЕИНА ШИПОВ SARS-CoV-2
HK1242713A1 (en) T cell activating bispecific antigen binding molecules agiant folr1 and cd3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220530

Address after: No. 15318, 95 Street northeast, Redmond, Washington, U. S.

Applicant after: Seattle Immunization Co.

Applicant after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Address before: No. 15318, 95 Street northeast, Redmond, Washington, U. S.

Applicant before: Seattle Immunization Co.

Applicant before: SICHUAN BAILI PHARM Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240623

Address after: No. 139 Baili Road, Chengdu Cross Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province, 611130

Patentee after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: 15318 Northeast 95th Street, Redmond, Washington, USA

Patentee before: Seattle Immunization Co.

Country or region before: U.S.A.

Patentee before: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region before: China

TR01 Transfer of patent right